Booster battle: moderna vs. novavax for fourth COVID shot
NCT ID NCT05658523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two different COVID-19 vaccines—Moderna's bivalent mRNA and Novavax's protein-based—as a fourth booster dose in healthy adults who have already had three doses. Researchers will check how well each vaccine boosts the immune system and track any side effects. The goal is to find out which booster is safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- COVID-19 vaccines (Moderna bivalent mRNA and Novavax protein-based)
- What this could lead to
- If successful, this could show which booster vaccine works best for a fourth dose, helping guide future vaccination strategies.
- What could go wrong
- This is a relatively small trial (496 people) and only measures short-term immune response and side effects, not long-term protection against infection or severe disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Children's Hospital, Murdoch Children's Research Institute
Melbourne, Victoria, 3052, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?